Summary
"GLUMON aims to leverage a new class of a biomedical optoacoustic sensor developed under the FETOpen project RSENSE (GA #862811) and offer the next generation of non-invasive biochemical in-vivo sensing. The preliminary sensor for non-invasive in-blood glucose sensing has already produced outstanding findings and places the technology well ahead of its competition. Addressing the limitations of existing sensors, mainly accurate non-invasive continuous monitoring of blood-glucose as well as comfort, the GLUMON sensor will better address diabetes healthcare needs. As a secondary goal and contingency plan, GLUMON will exploit this technology as a lipid sensor and build further potential by addressing the emerging precision nutrition market.
The objectives of the GLUMON project are to:
1) mature the technology from a lab bench-top setup to a functional portable sensor prototype;
2) improve its market readiness level;
3) validate and demonstrate the sensor in the lab as well as in preclinical and clinical settings;
4) develop a sound business case and exploitation strategy; and
5) address regulatory and ethical requirements for this medical device in preparation for the next phase.
The GLUMON consortium includes the key developers of the technology, two SMEs for prototyping, quality control and tech-to-market transition, and two university clinical partners for sensor validation. Key stakeholders (type-2 diabetes patients, patient advocacy groups, clinicians, health insurance) will be involved during the project to assess user needs and market requirements. Overall, the GLUMON sensor has the potential to play a critical role in future medicine by improving diabetes management and, more generally, by promoting new healthcare concepts in obesity and metabolic diseases, including early disease detection and home-based disease monitoring.
"
The objectives of the GLUMON project are to:
1) mature the technology from a lab bench-top setup to a functional portable sensor prototype;
2) improve its market readiness level;
3) validate and demonstrate the sensor in the lab as well as in preclinical and clinical settings;
4) develop a sound business case and exploitation strategy; and
5) address regulatory and ethical requirements for this medical device in preparation for the next phase.
The GLUMON consortium includes the key developers of the technology, two SMEs for prototyping, quality control and tech-to-market transition, and two university clinical partners for sensor validation. Key stakeholders (type-2 diabetes patients, patient advocacy groups, clinicians, health insurance) will be involved during the project to assess user needs and market requirements. Overall, the GLUMON sensor has the potential to play a critical role in future medicine by improving diabetes management and, more generally, by promoting new healthcare concepts in obesity and metabolic diseases, including early disease detection and home-based disease monitoring.
"
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101058111 |
| Start date: | 01-05-2022 |
| End date: | 30-04-2026 |
| Total budget - Public funding: | 2 344 210,50 Euro - 2 194 210,00 Euro |
Cordis data
Original description
"GLUMON aims to leverage a new class of a biomedical optoacoustic sensor developed under the FETOpen project RSENSE (GA #862811) and offer the next generation of non-invasive biochemical in-vivo sensing. The preliminary sensor for non-invasive in-blood glucose sensing has already produced outstanding findings and places the technology well ahead of its competition. Addressing the limitations of existing sensors, mainly accurate non-invasive continuous monitoring of blood-glucose as well as comfort, the GLUMON sensor will better address diabetes healthcare needs. As a secondary goal and contingency plan, GLUMON will exploit this technology as a lipid sensor and build further potential by addressing the emerging precision nutrition market.The objectives of the GLUMON project are to:
1) mature the technology from a lab bench-top setup to a functional portable sensor prototype;
2) improve its market readiness level;
3) validate and demonstrate the sensor in the lab as well as in preclinical and clinical settings;
4) develop a sound business case and exploitation strategy; and
5) address regulatory and ethical requirements for this medical device in preparation for the next phase.
The GLUMON consortium includes the key developers of the technology, two SMEs for prototyping, quality control and tech-to-market transition, and two university clinical partners for sensor validation. Key stakeholders (type-2 diabetes patients, patient advocacy groups, clinicians, health insurance) will be involved during the project to assess user needs and market requirements. Overall, the GLUMON sensor has the potential to play a critical role in future medicine by improving diabetes management and, more generally, by promoting new healthcare concepts in obesity and metabolic diseases, including early disease detection and home-based disease monitoring.
"
Status
SIGNEDCall topic
HORIZON-EIC-2021-TRANSITIONCHALLENGES-01-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
